Lung Cancer

Findings from Italy and France describe new data in lung cancer research

Published in Cancer Weekly, August 29th, 2006

Lung cancer research advances have been reported from Italy and France.

Study 1: Lung cancer patients pretreated with platinum and etoposide responded moderately to weekly paclitaxel and gemcitabine.

According to recent research published in the journal Cancer Chemotherapy and Pharmacology, "The safety and efficacy of a combined regimen of weekly paclitaxel and gemcitabine was tested in patients with refractory and sensitive small-cell lung cancer (SCLC). Treatment consisted of paclitaxel 80 mg/m² on days 1, 8, 15 and gemcitabine 1,000 mg/m² on days 1 and 8 every 3 weeks. Of the 31 patients enrolled, 10 had refractory and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry